Drug Trial Radar · NCT06852963
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
Last checked: Nov 19, 2026Latest source record: May 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Jun 1, 2025
Primary completion
Mar 8, 2028
Study completion Apr 21, 2028
Sponsor
- Lead sponsor
- PYC TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31 mutation-associated retinal dystrophy, including participants previously treated with VP001 in the PLATYPUS Study or WALLABY Study for a minimum of 8 weeks.
Conditions
- Retinitis Pigmentosa 11
- Retinal Degeneration
- Retinal Disease
- Eye Diseases Hereditary
- Retinal Dystrophies
Interventions
VP-001Drug
VP-001 is an oligonucleotide-peptide conjugate administered intravitreally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the safety of two doses of repeatedly administered intravitreally VP-001 in participants with confirmed PRPF31 mutation-associated retinal dystrophy.Time frame: 26 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
University of Florida College of Medicine
Jacksonville, Florida
Bascom Palmer Eye Institute - University of Miami
Miami, Florida
Kellogg Eye Center - University of Michigan
Ann Arbor, Michigan
Casey Eye Institute - OHSU
Portland, Oregon
Retina Foundation of the Southwest
Dallas, Texas
Baylor College of Medicine
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.